Genmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC Wainwright

Key Points

• HC Wainwright has restated a buy rating for Genmab A/S with a price target of $40.00, indicating a potential upside of 22.14% from its current trading price.
• Genmab A/S received multiple upgrades from research firms, with Zacks Research and Wall Street Zen raising their ratings to "strong-buy."
• Genmab A/S reported a net margin of 37.53% and earnings of $0.54 per share for the last quarter, surpassing market expectations of $0.39.

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 22.14% from the stock's current price.

Several other research firms have also recently commented on GMAB. Zacks Research upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Wall Street Zen upgraded shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, September 26th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Truist Financial raised their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target on the stock in a research report on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

Genmab A/S Price Performance

Shares of GMAB opened at $32.75 on Wednesday. The firm's 50 day moving average is $27.29 and its 200-day moving average is $23.07. The stock has a market capitalization of $21.03 billion, a P/E ratio of 16.46, a P/E/G ratio of 1.84 and a beta of 0.98. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.63.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. increased its position in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after acquiring an additional 440 shares during the period. Captrust Financial Advisors boosted its stake in Genmab A/S by 2.4% during the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company's stock worth $464,000 after buying an additional 526 shares in the last quarter. Rhumbline Advisers boosted its stake in Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company's stock worth $332,000 after buying an additional 532 shares in the last quarter. CWM LLC boosted its stake in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after buying an additional 603 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its stake in Genmab A/S by 7.8% during the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company's stock worth $226,000 after buying an additional 790 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.